Downey 2016.

Study characteristics
Methods	Randomised, double‐blind, placebo‐controlled, parallel‐groups trial
Participants	Diagnosis: DSM‐IV major depressive episode N: 60 (randomised) Age: lanicemine M = 26.7; ketamine M = 27.1; Placebo M = 25.7 Sex: lanicemine group 60% female; ketamine 61.9% female; Placebo group 57.9% female Baseline depression severity: lanicemine group BDI score M = 34.5 (SD = 9.3); Ketamine group BDI score M = 30.94 (SD = 7.1); Placebo group BDI score M = 25.72 (SD = 7.67)
Interventions	Participants received a constant intravenous infusion of lanicemine (100 mg total dose), ketamine (0.5 mg/kg total dose) or placebo (0.9% saline) each made up to 40 mL volume and infused for 60 minutes. Concomitant treatment: quote: "Participants were drug‐free but not drug naive"
Outcomes	BDI MADRS CADSS BOLD phMRI signal in the sgACC
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "participants were randomized". No further details given on randomisation procedure.
Allocation concealment (selection bias)	Low risk	Quote: "The research pharmacies at each site held separate randomization codes and dispensed the infusions on the day of the experiment labelled with a code number".
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "The research pharmacies at each site held separate randomization codes and dispensed the infusions on the day of the experiment labelled with a code number".
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information given.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Study reports dropouts (zero).
Selective reporting (reporting bias)	Unclear risk	No information given.
Other bias	High risk	Potential bias due to funding by pharmaceutical company. Quote: "This study was wholly sponsored by AstraZeneca".